MedTrace Logo

Treatment of Leukemia and Lymphoma in Children With Ataxia Telangiectasia

NCT04037189 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 250

Last updated 2021-10-01

No results posted yet for this study

Summary

Ataxia telangiectasia (A-T) is a multisystem disease with diverse manifestations, including progressive neurodegeneration, immunodeficiency, respiratory disease, and genomic instability. One of the most important features of A-T is the increased predisposition to cancer, especially to lymphoid malignancies. Patients with A-T are generally excluded from collaborative clinical trials, their treatment outcomes and toxicity profiles have rarely been reported, and little is currently known concerning the treatment intensity required to provide a reasonable balance between efficacy and toxicity. The aims of this study are to build a large international de-identified database of children with A-T treated for leukemia and lymphoma, to investigate epidemiology and outcome of treatment, toxicity profiles and risk factors which impact outcome, in order to eventually enable the generation of data-based treatment recommendations for this population.

Conditions

Sponsors & Collaborators

  • Israeli Society for Pediatric Hematology-Oncology

    collaborator OTHER

  • International BFM Study Group

    collaborator NETWORK

  • Rabin Medical Center

    lead OTHER

Principal Investigators

  • Sarah Elitzur, MD · Schneider Children's Medical Center, Israel

Eligibility

Min Age
0 Years
Max Age
21 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-07-28
Primary Completion
2021-10-28
Completion
2021-12-30

Countries

  • Israel

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04037189 on ClinicalTrials.gov